Tor Henrik Anderson Tvedt

Author information from the last article

Medisinsk klinikk

Haukeland universitetssjukehus

Avdeling for blodsykdommer

Oslo universitetssykehus

Forfatterbidrag: datainnsamling, tolking av data, revisjon av manuset og godkjenning av innsendte manusversjon.

Tor Henrik Anderson Tvedt er ph.d., spesialist i indremedisin og i blodsykdommer og overlege.

Articles by Tor Henrik Anderson Tvedt

High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008–2020

Jakob Nordberg Nørgaard,
Kari Lenita Falck Moore,
Tobias S. Slørdahl,
Anders Vik,
Tor Henrik Anderson Tvedt,
Hedda Berg Monsen,
Fredrik Schjesvold

13.04.2026: High-dose melphalan and autologous haematopoietic stem-cell transplantation (ASCT) has been used to treat multiple myeloma in Norway since the 1990s (1). In this treatment, the patient receives high-dose chemotherapy with melphalan, followed by reinfusion of the patient's previously harvested stem...

Allogeneic stem cell transplantation in adults 2015–21

Camilla Dao Vo,
Anders Eivind Myhre,
Ingerid Weum Abrahamsen,
Mats Remberger,
Jonas Mattsson,
Yngvar Fløisand,
Bjørn Christer Linder Grønvold,
Geir Erland Tjønnfjord,
Tor Henrik Anderson Tvedt,
Tobias Gedde-Dahl

14.03.2023: Allogeneic stem cell transplantation is the only curative treatment for a number of malignant haematological diseases and congenital or acquired immunodeficiencies. In allogeneic stem cell transplantation, the patient's own bone marrow is destroyed following pre-transplant treatment with high-dose...